Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cleopatra Hospital CoCAI:CLHO +1.61%87 3-Year EBITDA Growth Rate is 42.90% as of Mar. 2026, which is 79% above its 10-year median of 24.00. GuruFocus rates CAI:CLHO with a GF Score™ of 87/100 and a GF Value™ of E£14.66 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 526 Healthcare Providers & Services companies, Cleopatra Hospital Co ranks better than 87.64% on this metric.
During the past 12 months, Cleopatra Hospital Co's average EBITDA Per Share Growth Rate was 17.40% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 42.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 32.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 13.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cleopatra Hospital Co was 42.90% per year. The lowest was -42.20% per year. And the median was 24.00% per year.
Cleopatra Hospital Co (CAI:CLHO) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Cleopatra Hospital Co 3-Year EBITDA Growth Rate Related Terms
CAI:CLHO vs HCA, THC, DVA: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, Cleopatra Hospital Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cleopatra Hospital Co 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cleopatra Hospital Co's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Cleopatra Hospital Co's 3-Year EBITDA Growth Rate falls into.
Cleopatra Hospital Co 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 42.90% mean?
Cleopatra Hospital Co (CAI:CLHO) has a 3-Year EBITDA Growth Rate of 42.90% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cleopatra Hospital Co and its competitors. This is 79% above median its historical median of 24.00. According to the industry distribution chart, Cleopatra Hospital Co ranks #65 out of 526 companies in the Healthcare Providers & Services industry, placing it in the top 12.4%.
Is Cleopatra Hospital Co's 3-Year EBITDA Growth Rate too high?
Cleopatra Hospital Co's current 3-Year EBITDA Growth Rate of 42.90% is 79% above median its 10-year median of 24.00. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.05. Cleopatra Hospital Co's value of 42.90% is 326.9% above this industry median. Based on the distribution chart, Cleopatra Hospital Co ranks #65 out of 526 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Cleopatra Hospital Co has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cleopatra Hospital Co's 3-Year EBITDA Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Cleopatra Hospital Co ranks #65 out of 526 companies for 3-Year EBITDA Growth Rate. This places Cleopatra Hospital Co in the top 12% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 10.05. Cleopatra Hospital Co's value of 42.90% is 326.9% above this benchmark. While the company's 10-year median is 24.00 vs. the industry median of 10.05, Cleopatra Hospital Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.05, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cleopatra Hospital Co's current 3-Year EBITDA Growth Rate of 42.90% is 326.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cleopatra Hospital Co and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cleopatra Hospital Co's current 3-Year EBITDA Growth Rate is 42.90%, which is 79% above median its own 10-year median of 24.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cleopatra Hospital Co stock overvalued right now?
Based on GuruFocus' analysis, Cleopatra Hospital Co (CAI:CLHO) is currently considered Modestly Overvalued. The stock's GF Value™ is E£14.66, compared to a current price of E£17.71 — trading 20.8% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 42.90%, which is 79% above median its 10-year median of 24.00 and 326.9% above the Healthcare Providers & Services industry median of 10.05. Cleopatra Hospital Co's overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Cleopatra Hospital Co (CAI:CLHO), the current 3-Year EBITDA Growth Rate is 42.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cleopatra Hospital Co (CAI:CLHO) Overvalued in 2026?
Based on GuruFocus' analysis, Cleopatra Hospital Co stock appears to be overvalued.
The current stock price of E£17.71 is trading 20.8% above its estimated GF Value™ of E£14.66.
GuruFocus considers Cleopatra Hospital Co to be Modestly Overvalued.
Key valuation signals for CAI:CLHO:
3-Year EBITDA Growth Rate: 42.90% (79% above median its 10-year median of 24.00)
GF Value™: E£14.66 vs. price of E£17.71 (20.8% above fair value)
Industry Position: 326.9% above the Healthcare Providers & Services median (#65 of 526)
No single metric tells the full story. See the CAI:CLHO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cleopatra Hospital Co establishes a private hospital to provide modern health and medical services, in addition to medical care for inpatients. The company's segments include Cleopatra Hospital Company, Cairo Specialised Hospital, Nile Badrawy Hospital, Al Shrouk Hospital, CHG Medical Services, CHG Pharma for Pharmacy Management, CHG for Hospitals Company, Queens Hospital, ElKateb Hospital, Bedaya El Gedida Company for Medical Centers and Hospitals, CHG SKY Hospital, and Cleopatra Heaven.
87GF Score
Get the complete analysis for CAI:CLHO
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:CLHO has been successfully added to your 
